Phase 1b Study of Venetoclax with Decitabine or Azacitidine for Elderly Patients with Untreated AML
DiNardo C et al. A Phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Proc ASH 2015;Abstract 327.
Dr Stone is Director of the Adult Leukemia Program at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School in Boston, Massachusetts.
|